Compare · CBLI vs IQV
CBLI vs IQV
Side-by-side comparison of Cleveland BioLabs, Inc. (CBLI) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLI and IQV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $42.70B, about 804.3x CBLI ($53.1M).
- IQV has hit the wire 6 times in the past 4 weeks while CBLI has been quiet.
- IQV has more recent analyst coverage (25 ratings vs 0 for CBLI).
- Company
- Cleveland BioLabs, Inc.
- IQVIA Holdings Inc.
- Price
- -
- -
- Market cap
- $53.1M
- $42.70B
- 1M return
- -
- +21.69%
- 1Y return
- -
- +38.18%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- 2013
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest CBLI
- SEC Form 4: Barbarick Steve K was granted 60,000 shares
- SEC Form 4: Verny Lea was granted 60,000 shares
- SEC Form DEF 14A filed by Cleveland BioLabs, Inc.
- SEC Form 4: Markvicka Taunia was granted 100,000 shares
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Cleveland BioLabs, Inc.
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest IQV
- IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
- IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
- Officer Staub W Richard sold $1,279,740 worth of shares (5,500 units at $232.68), decreasing direct ownership by 29% to 13,312 units (SEC Form 4)
- Officer Patel Bhavik sold $436,426 worth of shares (1,855 units at $235.27), decreasing direct ownership by 58% to 1,348 units (SEC Form 4)
- IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
- SEC Form 144 filed by IQVIA Holdings Inc.
- Officer Sherbet Eric sold $1,245,800 worth of shares (5,000 units at $249.16), decreasing direct ownership by 19% to 20,999 units (SEC Form 4)
- Officer Cherofsky Keriann sold $136,827 worth of shares (558 units at $245.21), decreasing direct ownership by 16% to 2,989 units (SEC Form 4)
- Officer Bousbib Ari exercised 156,206 shares at a strike of $78.21, sold $26,092,072 worth of shares (106,279 units at $245.51) and returned $12,217,110 worth of shares to the company (49,927 units at $244.70) (SEC Form 4)
- SEC Form 144 filed by IQVIA Holdings Inc.